Trials / Completed
CompletedNCT02197806
Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 40 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-199201 | 1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol. |
| DRUG | AGN-190584 | 1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol. |
| DRUG | AGN-199201 Vehicle | 1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol. |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2014-10-01
- Completion
- 2014-11-01
- First posted
- 2014-07-23
- Last updated
- 2015-12-03
- Results posted
- 2015-12-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02197806. Inclusion in this directory is not an endorsement.